COMMENTARY

As Japan’s Contract Drug Rep Ratio Rises, Expectations Grow for Specialist Talent and Flexible Workforce

By Tatsuya Otsuka August 5, 2025

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

Japan’s contract drug rep ratio rose to 8.7% in FY2024 as the total number of regular reps continued to fall, the Japan Contract Sales Organization Association (JCSOA) reported in June. Amid industry downsizing, the roles and expectations placed on contract…

To read the full story

Japan’s Contract Rep Ratio Hits Record as Biotechs, Foreign Firms Drive Demand
July 1, 2025

COMMENTARY

Wave of “World Firsts” Looms as 47 New Drug Candidates Line Up for 2026
January 6, 2026
Radioligand Therapy Faces Capacity Bottleneck in Japan, System Build-Out Needed to Deliver on Promise
December 22, 2025
FY2026 Reform Debate for Drug Pricing Nears the Finish Line, Balance Needed
December 9, 2025
MOF Autumn Proposals Signal a Shift from Drug Pricing to Cost-Sharing Reform
November 17, 2025
Japan’s Trading Houses Gain Ground in Pharma, Rewriting the Industry Playbook
November 10, 2025

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo Backs Draft FY2026 Pricing Reform Outline, Rejects Key Industry Requests

By Takashi Ebisawa

The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…

COLUMN

AI: Your New HR BFF (Not Your Replacement!)

By Philip Carrigan

Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…

COMMENTARY

Radioligand Therapy Faces Capacity Bottleneck in Japan, System Build-Out Needed to Deliver on Promise

By Koji Shimomura

Novartis’ Pluvicto (lutetium vipivotide tetraxetan (177Lu)) won reimbursement listing in Japan in November as a radioligand therapy (RLT) for PSMA-positive…